Intravascular imaging analysis of a drug-eluting balloon followed by a bare metal stent compared to a drug-eluting stent for treatment of de novo lesions
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: After a study comparing drug-eluting stents (DESs) to sequential treatment with drug-eluting balloons (DEBs) and bare metal stents (BMSs), we retrospectively analysed strut malapposition and neointimal hyperplasia in de novo coronary lesions using optical coherence tomography (OCT) or intravascular ultrasonography (IVUS). Methods: We obtained OCT data from 16 patients (eight per group) and IVUS data from 40 patients (20 per group). OCT or IVUS was performed after the index procedure and after 9 months. Parameters including obstruction volume due to neointimal hyperplasia (neointimal hyperplasia volume/stent volume, %), strut malapposition (% of malapposed struts), and intra-individual inhomogeneity of in-stent restenosis were compared. Results: Although obstruction volume due to neointimal hyperplasia was significantly higher in the DEB-BMS group (14.90 ± 15.36 vs. DES 7.03 ± 11.39, p = 0.025), there was no difference in strut malapposition between the two groups (DEB-BMS 1.99 ± 5.37 vs. DES 0.88 ± 2.22, p = 0.856). The DEB-BMS group showed greater intra- individual inhomogeneity of in-stent restenosis pattern than the DES group. Conclusions: Treatment with DEB followed by BMS failed to improve strut malapposition despite higher in-stent neointimal growth, probably because of the inhomogeneous inhibition of in-stent neointimal hyperplasia by DEB. DEB technology should be improved to obtain even drug delivery to the vessel wall and homogeneous prevention of neointimal growth comparable to contemporary DES.
Abstract
Background/Aims: After a study comparing drug-eluting stents (DESs) to sequential treatment with drug-eluting balloons (DEBs) and bare metal stents (BMSs), we retrospectively analysed strut malapposition and neointimal hyperplasia in de novo coronary lesions using optical coherence tomography (OCT) or intravascular ultrasonography (IVUS). Methods: We obtained OCT data from 16 patients (eight per group) and IVUS data from 40 patients (20 per group). OCT or IVUS was performed after the index procedure and after 9 months. Parameters including obstruction volume due to neointimal hyperplasia (neointimal hyperplasia volume/stent volume, %), strut malapposition (% of malapposed struts), and intra-individual inhomogeneity of in-stent restenosis were compared. Results: Although obstruction volume due to neointimal hyperplasia was significantly higher in the DEB-BMS group (14.90 ± 15.36 vs. DES 7.03 ± 11.39, p = 0.025), there was no difference in strut malapposition between the two groups (DEB-BMS 1.99 ± 5.37 vs. DES 0.88 ± 2.22, p = 0.856). The DEB-BMS group showed greater intra- individual inhomogeneity of in-stent restenosis pattern than the DES group. Conclusions: Treatment with DEB followed by BMS failed to improve strut malapposition despite higher in-stent neointimal growth, probably because of the inhomogeneous inhibition of in-stent neointimal hyperplasia by DEB. DEB technology should be improved to obtain even drug delivery to the vessel wall and homogeneous prevention of neointimal growth comparable to contemporary DES.
참고문헌 (29)
- Morice MC, "Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions : a randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization", N Engl J Med, 346, pp.1773~1780 (2002)
- Moses JW, "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery", N Engl J Med, 349, pp.1315~1323 (2003)
- Windecker S, "Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization", N Engl J Med, 353, pp.653~662 (2005)
- Fajadet J, "Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions : clinical and angiographic results of the ENDEAVOR II trial", Circulation, 114, pp.798~806 (2006)
- Iakovou I, "Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents", JAMA, 293, pp.2126~2130 (2005)
- Higo T, "Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent : an angioscopic study", JACC Cardiovasc Imaging, 2, pp.616~624 (2009)
- Hassan AK, "Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis", Eur Heart J, 31, pp.1172~1180 (2010)
- Scheller B, "Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis", Circulation, 110, pp.810~814 (2004)
- Unverdorben M, "Treatment of small coronary arteries with a paclitaxel-coated balloon catheter", Clin Res Cardiol, 99, pp.165~174 (2010)
- Mathey DG, "Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial", EuroIntervention, (7 Suppl K), pp.K61~K65 (2011)
- Kastrati A, "Intracoronary stenting and angiographic results : strut thickness effect on restenosis outcome(ISAR-STEREO)trial", Circulation, 103, pp.2816~2821 (2001)
- Pache J, "Intracoronary stenting and angiographic results : strut thickness effect on restenosis outcome(ISAR-STEREO-2)trial", J Am Coll Cardiol, 41, pp.1283~1288 (2003)
- Poss J, "Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010 : FAIR-HF, CIPAMI, LIPSIA-NSTEMI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis", Clin Res Cardiol, 99, pp.411~417 (2010)
- 채인호, "Comparison of Drug-Eluting Balloon Followed by Bare Metal Stent with Drug-Eluting Stent for Treatment of de Novo Lesions: Randomized, Controlled, Single-Center Clinical Trial", Journal of Korean Medical Science, 32(6), pp.933~941 (2017), 대한의학회
- Tearney GJ, "Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies : a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation", J Am Coll Cardiol, 59, pp.1058~1072 (2012)
- Takano M, "Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation", Am Cardiol, 99, pp.1033~1038 (2007)
- Xie Y, "Comparison of neointimal coverage by optical coherence tomography of a sirolimus-eluting stent versus a bare-metal stent three months after implantation", Am J Cardiol, 102, pp.27~31 (2008)
- Prati F, "Expert review document on methodology, terminology, and clinical applications of optical coherence tomography : physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis", Eur Heart J, 31, pp.401~415 (2010)
- Kang SJ, "Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation", Circulation, 123, pp.2954~2963 (2011)
- Ohtani H, "Comparison of vascular responses after different types of second-generation drug-eluting stents implantation detected by optical coherence tomography", Int J Cardiovasc Imaging, 33, pp.177~186 (2017)
- Kim S, "Comparison of early strut coverage between zotarolimus-and everolimus-eluting stents using optical coherence tomography", Am J Cardiol, 111, pp.1~5 (2013)
- Masawa T, "Comparison of the performance of zotarolimus-and everolimus-eluting stents by optical coherence tomography and coronary angioscopy", Heart Vessels, 31, pp.1230~1238 (2016)
- Posa A, "Attainment of local drug delivery with paclitaxel-eluting balloon in porcine coronary arteries", Coron Artery Dis, 19, pp.243~247 (2008)
- Kleber FX, "Drug-coated balloons for treatment of coronary artery disease : updated recommendations from a consensus group", Clin Res Cardiol, 102, pp.785~797 (2013)
- Wohrle J, "Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease", Heart, 97, pp.1338~1342 (2011)
- Xu B, "Zotarolimus-and paclitaxel-eluting stents in an all-comer population in China : the RESOLUTE China randomized controlled trial", JACC Cardiovasc Interv, 6, pp.664~670 (2013)
- Solinas E, "Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention", Am J Cardiol, 102, pp.311~315 (2008)
- Levine GN, "2011 ACCF", AHA, American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions, pp.Circulation, 2011[DOI]
- Urban P, "Polymer-free drug-coated coronary stents in patients at high bleeding risk", N Engl J Med, 373, pp.2038~2047 (2015)